These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29164326)

  • 1. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
    Cremers RG; Aben KK; van Oort IM; Sedelaar JP; Vasen HF; Vermeulen SH; Kiemeney LA
    Prostate; 2016 Jul; 76(10):897-904. PubMed ID: 26989049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
    Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
    Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer.
    Heck MM; Kron M; Gschwend JE; Herkommer K
    Eur J Cancer; 2012 Jun; 48(9):1312-7. PubMed ID: 22056636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
    Sooriakumaran P; Haendler L; Nyberg T; Gronberg H; Nilsson A; Carlsson S; Hosseini A; Adding C; Jonsson M; Ploumidis A; Egevad L; Steineck G; Wiklund P
    Eur Urol; 2012 Nov; 62(5):768-74. PubMed ID: 22633365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
    Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
    BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy.
    Bova GS; Partin AW; Isaacs SD; Carter BS; Beaty TL; Isaacs WB; Walsh PC
    J Urol; 1998 Sep; 160(3 Pt 1):660-3. PubMed ID: 9720516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
    Bolton DM; Ta A; Bagnato M; Muller D; Lawrentschuk NL; Severi G; Syme RR; Giles GG
    World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
    Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
    Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.
    Cheney MD; Zhang D; Chen MH; Loffredo MJ; Richie JP; D'Amico AV
    Clin Genitourin Cancer; 2015 Aug; 13(4):338-343. PubMed ID: 25862320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer biochemical recurrence rates after robotic-assisted laparoscopic radical prostatectomy.
    Ginzburg S; Nevers T; Staff I; Tortora J; Champagne A; Kesler SS; Laudone VP; Wagner JR
    JSLS; 2012; 16(3):443-50. PubMed ID: 23318071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.